Vir Biotechnology Statistics
Share Statistics
Vir Biotechnology has 144.95M shares outstanding. The number of shares has increased by 1.58% in one year.
| Shares Outstanding | 144.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 87.70M |
| Failed to Deliver (FTD) Shares | 297 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 5.72M, so 4.15% of the outstanding shares have been sold short.
| Short Interest | 5.72M |
| Short % of Shares Out | 4.15% |
| Short % of Float | 6.55% |
| Short Ratio (days to cover) | 7.28 |
Valuation Ratios
The PE ratio is -2.19 and the forward PE ratio is -2.48.
| PE Ratio | -2.19 |
| Forward PE | -2.48 |
| PS Ratio | 15.66 |
| Forward PS | 33.3 |
| PB Ratio | 0.85 |
| P/FCF Ratio | -1.69 |
| PEG Ratio | n/a |
Enterprise Valuation
Vir Biotechnology Inc. has an Enterprise Value (EV) of 1.22B.
| EV / Earnings | -1.98 |
| EV / Sales | 14.15 |
| EV / EBITDA | -1.83 |
| EV / EBIT | -1.78 |
| EV / FCF | -1.52 |
Financial Position
The company has a current ratio of 9.05, with a Debt / Equity ratio of 0.
| Current Ratio | 9.05 |
| Quick Ratio | 9.05 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on capital (ROIC) is -39.08%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -39.08% |
| Revenue Per Employee | 146.81K |
| Profits Per Employee | -1.05M |
| Employee Count | 587 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -13.08M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by -25.1% in the last 52 weeks. The beta is 0.46, so Vir Biotechnology 's price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | -25.1% |
| 50-Day Moving Average | 8.02 |
| 200-Day Moving Average | 9 |
| Relative Strength Index (RSI) | 43.61 |
| Average Volume (20 Days) | 1.21M |
Income Statement
In the last 12 months, Vir Biotechnology had revenue of $86.18M and earned -$615.06M in profits. Earnings per share was $-4.59.
| Revenue | 86.18M |
| Gross Profit | 83.42M |
| Operating Income | -684.30M |
| Net Income | -615.06M |
| EBITDA | -664.85M |
| EBIT | -684.30M |
| Earnings Per Share (EPS) | -4.59 |
Balance Sheet
The company has $254.84M in cash and $124.54M in debt, giving a net cash position of $130.30M.
| Cash & Cash Equivalents | 254.84M |
| Total Debt | 124.54M |
| Net Cash | 130.30M |
| Retained Earnings | -237.82M |
| Total Assets | 1.50B |
| Working Capital | 930.00M |
Cash Flow
In the last 12 months, operating cash flow was -$778.78M and capital expenditures -$21.57M, giving a free cash flow of -$800.36M.
| Operating Cash Flow | -778.78M |
| Capital Expenditures | -21.57M |
| Free Cash Flow | -800.36M |
| FCF Per Share | -5.97 |
Margins
Gross margin is 96.79%, with operating and profit margins of -794.04% and -713.69%.
| Gross Margin | 96.79% |
| Operating Margin | -794.04% |
| Pretax Margin | -728.93% |
| Profit Margin | -713.69% |
| EBITDA Margin | -771.47% |
| EBIT Margin | -794.04% |
| FCF Margin | -928.71% |
Dividends & Yields
VIR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -61.53% |
| FCF Yield | -74.02% |
Analyst Forecast
The average price target for VIR is $17, which is 127.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 127.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 2 |